Objective: The purpose of this study was to investigate the roles of the kallikrein-kinin system and matrix metalloproteinases (MMPs) in the development of arterial restenosis attributable to intimal hyperplasia in the femoropopliteal arteries.
Covered stents are composed of fabric or synthetic material supported by a metal mesh or stent platform. Although initially conceived to exclude peripheral arterial aneurysms and treat vessel perforations, 1 the use of covered stents has expanded to act as a barrier to neointimal formation by excluding the vessel wall from the lumen. One such device is the Viabahn endoprosthesis (W. L. Gore & Associates, Flagstaff, Ariz), a tube of expanded polytetrafluoroethylene with a self-expanding helical nitinol stent mounted to the outside surface. Microporous polytetrafluoroethylene coating of stent surfaces has been found to inhibit the development of in-stent restenosis in the femoropopliteal (FP) segment, and clinical data suggest that polytetrafluoroethylenecovered stents can lead to better patency rates than angioplasty using bare metal stents for this very challenging segment. 2, 3 Stenting of the FP segment has been associated with a more intense inflammatory response than the same procedure for the iliac and carotid arteries. 4 Study results have consistently indicated that inflammatory mechanisms play a key role in the proliferative process associated with neointimal and restenosis after stent placement. [5] [6] [7] Inflammatory markers have been studied to better understand the process and potentially identify future therapeutic interventions. The kallikrein-kinin system (KKS) is an endogenous metabolic cascade leading to the release of vasoactive kinins. This complex system includes the precursors of kinins, known as kininogens, and the kallikrein serine proteases. Kinins exhibit both proinflammatory and cardioprotective activity and are involved in a variety of physiological and pathologic processes, including blood pressure control, the coagulation cascade, and inflammation. 8 Kinins are rapidly hydrolyzed by a group of peptidases known as kininases. Kininase II, also known as angiotensin-converting enzyme (ACE), is the most studied kininase and functions to degrade the biologically active kinins, notably bradykinin (BK). Kininase II also acts to convert angiotensin (Ang) I to Ang II. Through various mechanisms, Ang II plays a role in endothelial dysfunction. 9 The relationships between inflammatory and immune responses and adverse clinical events after stenting, principally in peripheral arteries, have yet to be defined. The matrix metalloproteinases (MMPs) are a family of zincdependent endopeptidases that are widely known for their ability to degrade various protein components of the extracellular matrix and promote its remodeling. 10 Unbalanced MMP activity promotes atherosclerotic processes, including cell migration, proliferation of vascular smooth muscle, and infiltration of vessel walls by inflammatory cells. 11, 12 The inhibition of MMP activity has been proposed as a pharmacologic approach for the treatment of cardiovascular disease. 13, 14 MMP-2 and MMP-9
have both been reported to play specific and important roles in various cardiovascular diseases. 15 The tissue inhibitors of metalloproteinases (TIMPs) are small proteins (w23 kDa) that interact with the zinc binding site within the catalytic domain of the active MMP at molar equivalence. Four TIMPs have been described: TIMP-1, TIMP-2, TIMP-3, and TIMP-4. Overall, the TIMPs are not specific for any particular MMP; however, TIMP-2 tends to interact with MMP-2, and TIMP-1 tends to interact with MMP-9.
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There are few specific studies of inflammation system following percutaneous transluminal angioplasty (PTA) with stent placement (PTA/stenting) to treat peripheral arterial disease specially using covered stents. The aim of this study was to investigate the systemic inflammatory response and the relationship between possible inflammatory markers and in-stent early restenosis in patients within 6 months of undergoing femoral PTA with covered stent implantation through a study of the serum kallikrein-kinin and metalloproteinase systems.
METHODS
We performed a single-center prospective study at the Department of Surgery and Anatomy, Division of Vascular and Endovascular Surgery, Ribeirão Preto Medical School, University of São Paulo in Brazil between July 2012 and September 2014. The institutional ethics committee approved the study, and each patient provided signed informed consent before participation.
Inclusion criteria. Selected patients were those with severe claudication, pain at rest, and/or ischemic ulceration not exceeding the digits of the foot (Rutherford stages 3, 4, and 5) who exhibited angiographic evidence of FP occlusion disease in the absence of any significant proximal disease. Patients were only included if they satisfied the TransAtlantic Inter-Society Consensus criteria (TASC) II for endovascular intervention (A, B, and C lesions).
Exclusion criteria. Patients were excluded if they had acute or chronic inflammatory disease, severe ischemic ulcers or extensive gangrene (Rutherford stage 6), TASC D lesions, if they primarily underwent local thrombolysis, or if they developed other arterial major complications (acute thrombotic events in other arterial segments not related to the site of stent implantation) in up to 6 months after stent implantation.
Laboratory examinations. Peripheral venous blood samples were obtained immediately before stent implantation and 24 hours and 6 months after the procedure. Blood was delivered into plastic tubes with sodium citrate for analysis of kallikrein and kininogens and into tubes with sodium heparin for analysis of MMPs, TIMPs, and ACE.
High-and low-molecular-weight kininogens. Total kininogen, low-molecular-weight kininogens (LMWK), and high-molecular-weight kininogens (HMWK) concentrations were determined by immunoenzymatic methods. LMWK concentrations were determined for plasma samples previously incubated (30 minutes) with kaolin (1.5 mg/mL). Before the determination of total and LMWK concentrations, respective untreated and kaolintreated plasma samples were submitted to acid denaturation and trypsin hydrolysis as previously described. 17 The concentration of released BK was measured using an enzyme-linked immunosorbent assay that employed an antibody against BK (Markit M; Dainippon Pharmaceutical, Osaka, Japan). 17 The concentration of HMWK was calculated by subtracting the plasma concentration of LMWK from the total kininogen plasma concentration. The results are expressed as mEq BK/mL plasma.
Plasma kallikrein. Plasma pre-kallikrein was activated to kallikrein and evaluated for amidase activity on the selective chromogenic substrate H-D-Pro-Phe-Arg-pnitroanilide (S-2302; Chromogenix, Mondal, Sweden). The paranitroaniline formed in this reaction was detected spectrophotometrically at 405 nm. The results are expressed as units (U) of kallikrein/mL plasma (U/mL) using a purified human PKal standard (Chromogenix). 18 To verify that the reactivity was due to PKal, additional reactions were performed in the presence or absence of soybean trypsin inhibitor (Sigma, St Louis, Mo).
Tissue kallikrein. To assay plasma tissue kallikrein activity, the plasma amidase activity of kallikrein was measured using the chromogenic substrate H-D-Val-Leu-Arg-paranitroanilide (S-2266; Chromogenix) in the presence or absence of aprotinin (Sigma), a tissue inhibitor of kallikrein, as previously described. 19 The paranitroaniline formed by this reaction was detected at 405 nm by spectrophotometry. Kallikrein tissue activity was calculated by subtracting the value determined in the presence of aprotinin from the value determined in the absence of aprotinin. The results are expressed as mM pNa/mL plasma.
Kininase II. Plasma kininase II activity was determined in plasma samples using the substrate hipuryl-Lhistidyl-L-leucine (Hip-His-Leu) and a fluorometric assay as described previously. 19, 20 The results are expressed as nMol His-Leu/mL plasma/minutes.
MMPs. Quantification of MMPs was performed by zymography, an electrophoresis technique. 21 MMP-2
and MMP-9 proform gelatinolytic activity was identified as unstained bands at 72 and 92 kDa, respectively, against a background of Coomassie blue-stained gelatin, using the Kodak Electrophoresis Documentation and Analysis System 290 (Kodak, Rochester, NY). The bands were evaluated using the Image J program, and the values were normalized by dividing by the standards run on each gel. The final values are expressed as arbitrary units.
Tissue inhibitor of metalloproteinases. The concentrations of TIMP-1 and -2 were determined using Quantikine Immunoassays (DTM100 and DTM200, respectively; R & D Systems, Minneapolis, Minn) according to the manufacturer instructions. Briefly, plasma samples were incubated with recombinant enzymes for 2 hours at room temperature in 96-well plates coated with a monoclonal antibody, followed by peroxidaseconjugated secondary antibody for 1 hour. A colorimetric substrate was added to each well, and the color change was measured in a spectrophotometer. TIMP-1 and -2 concentrations are expressed as ng/mL.
Procedures. Diagnostic and therapeutic procedures were performed with the patient under local anesthesia by the same team for all patients and following the institutional protocols for vascular interventions. Before undergoing PTA with stent implantation, every patient received dual antiplatelet therapy (aspirin 100 mg/day þ clopidogrel 75 mg/day) the day before the procedure or earlier. After puncture of the ipsilateral or contralateral femoral artery and insertion of a 6F or 7F sheath, a bolus of 5000 IU of intravenous heparin was administered followed by infusion of a lowosmolality nonionic contrast agent (Iopamiron 300; Bracco Imaging S.p.A., Ferentino, Italy). A hydrophilic .035-inch guidewire was used to cross the lesions, and predilatation was performed before stenting, using an appropriately sized balloon. The lesion was entirely covered by a single self-expandable coated stent (Viabahn endoprosthesis; W. L. Gore & Associates). After stent placement, postdilatation was performed in residual stenosis. After the procedure, each patient was prescribed lifelong aspirin therapy (100 mg/day) and clopidogrel (75 mg/day) and cilostazol (100 mg twice a day) for 6 months.
Follow-up. All patients were clinically followed for 6 months in the outpatient clinic. Recurrence of symptoms associated with decreases in ankle-brachial index > 0.15 and duplex ultrasound scan showing an incremental increase in the peak systolic velocity ratio of > 2.5-fold between adjacent arterial segments were criteria consistent with a significant restenosis. Diagnostic angiography was performed in all cases that met these criteria for restenosis with noninvasive tests. Postoperative angiographic images were compared with the previous images using a software program (K-PACS Image Information Systems; London, United Kingdom). A patient was confirmed to have developed restenosis if there was greater than 50% luminal narrowing in angiography images.
Statistical analyses. Results are expressed as the mean 6 standard deviation or proportions. The Shapiro-Wilk test was used to verify the normal distribution of data. To compare the proportions of categorical variables, Fisher exact test was used. To compare continuous variables, the t-test for independent groups or the paired t-test was used after considering the presence or absence of homoscedasticity; the nonparametric Mann-Whitney and Wilcoxon tests were used for variables with non-normal distributions. IBM SPSS v 20.0 software (Armonk, NY) was used for analysis. Significance was set at P ¼ .05.
RESULTS
Baseline characteristics. Of the 27 patients who completed the study, four patients developed restenosis (15%) and 23 patients did not have restenosis (85%) at the 6-month evaluation. There were no stent fractures. Besides the restenosis, none of the four patients showed significant clinical worsening. Patients with restenosis were younger (52.7 vs 68.6 mean years of age; P < .01); otherwise the differences in baseline characteristics, including cardiovascular risk factors and medication, of the patients with and without restenosis were not significant (Table I ). The baseline characteristics of the patients' FP lesions, including Rutherford and TASC II classifications, initial stenosis or occlusion, tibial peroneal runoff (two or three runoff vessels), and length of the stent used in the patients with and without restenosis are presented in Table II . Patients with restenosis had a higher proportion of TASC A lesions (P < .05) than the patients without restenosis. Considering that there were no angiographic differences from runoff between groups, we could only assume that the clinical control of patients with restenosis may not have been so appropriate as other individuals who did not have restenosis.
HMWK and LMWK. HMWK levels of patients with restenosis at 24 hours after PTA/stenting were significantly lower (P ¼ .02) than the levels of patients without restenosis. The HMWK levels of patients with restenosis were significantly decreased from baseline to 6 months after PTA/stenting (P ¼ .04) and from 24 hours to 6 months (P ¼ .002); in the patients without restenosis, the levels exhibited significant respective decreases from baseline to 24 hours to 6 months (P < .001) and from 24 hours to 6 months (P < .001) (Fig 1) . LMWK levels in patients with restenosis before, at 24 hours, and 6 months after PTA/stenting were lower than the levels of patients without restenosis. The LMWK levels of both the patients with and without restenosis decreased significantly from baseline to 24 hours (P ¼ .04; P < .001, respectively), from baseline to 6 months (P ¼ .01; P < .001, respectively), and from 24 hours to 6 months (P ¼ .03; P < .001, respectively) (Fig 1) .
Kallikrein. There were no significant differences between the patients with and without restenosis with respect to the levels of plasma and tissue kallikrein activity. The respective plasma kallikrein levels of patients with restenosis were significantly decreased from baseline to 24 hours to 6 months (P ¼ .04); in the patients without restenosis, there were significant decreases from baseline to 24 hours to 6 months (P < .001) and from 24 hours to 6 months (P < .001; Fig 2) .
The respective tissue kallikrein levels of patients with restenosis were significantly decreased from baseline to 24 hours to 6 months (P ¼ .002) and from 24 hours to 6 months (P < .03); in the patients without restenosis, there were significant decreases from baseline to 24 hours to 6 months (P < .001) and from 24 hours to 6 months (P < .001; Fig 2) .
Kininase II. There was no significant difference in the activity levels of kininase II between the patients with and without restenosis; however, for both groups, there were significant increases in the levels of enzyme activity over time. The respective levels of the patients with restenosis increased from baseline to 24 hours to 6 months; in the patients without restenosis, they increased from baseline to 24 hours to 6 months (P < .001) and from 24 hours to 6 months (P < .001; Fig 3) .
MMPs. There were no significant differences in the concentrations of MMP-2 or MMP-9 between the patients with and without restenosis. In addition, there were no significant differences in concentrations over time, as shown in Fig 4, except for MMP-2 . There was an increase in the MMP-2 level from baseline to 6 months (P ¼ .04) in patients without restenosis (Fig 4) .
TIMPs. There were no significant differences in the concentration of TIMP-1 between the patients with and without restenosis at any time point. However, there were higher levels of TIMP-1 in the restenosis patients at all time points, consistent with the higher Fig 1. A, High-molecular-weight kininogen (HMWK) concentration in patients undergoing percutaneous transluminal angioplasty (PTA)/covered stenting. B, Lowmolecular-weight kininogen (LMWK) concentration in patients undergoing PTA/covered stenting. a P < .05, before vs 6 months. b P < .05, 24 hours vs 6 months. c P < .05 before vs 24 hours. d P < .05 restenosis vs no restenosis. Blood samples for plasma were collected immediately before and 24 hours and 6 months after the procedure. The bars indicate the mean and standard deviation. activity of MMP-9 of these patients. At 6 months after the initial procedure, the TIMP-2 levels of the patients with restenosis were significantly lower than those of the patients without restenosis at 6 months (P ¼ .04) (Fig 5) .
The respective TIMP-1 levels of the patients without restenosis decreased significantly from baseline to 6 months (P ¼ .02) and from 24 hours to 6 months (P ¼ .1) (Fig 5) .
DISCUSSION
The role of covered stents in the treatment of occlusive disease of the superficial femoral artery remains controversial. Several studies have reported satisfactory results after PTA followed by placement of covered stents in the FP segment, including lower rates of restenosis compared with the placement of bare metal stents. 2, 3 A study by Araújo et al 16 found restenosis rates of 38.5%
after the placement of nitinol stents for the same arterial b P < .05, 24 hours vs 6 months. d P < .05, restenosis vs no restenosis. Blood samples for plasma were collected immediately before and 24 hours and 6 months after the procedure. The bars indicate the mean and standard deviation. segment, which is higher than the restenosis rate of our study (15%). Studies have reported rates of restenosis of up to 60% during the first year after PTA. 22, 23 The KKS is a complex cascade of enzymes that produce multiple bioactive peptide/kinins and their derivatives, including BK. In addition to the classical notion of the KKS as a vasodilator and potent mediator of inflammatory responses, the results of recent studies suggest that there is a link between the KKS and oxidative stress and organ damage in the heart and kidney. 24 However, the functional role of the KKS in vascular physiology has not been fully established. With respect to the KKS components we studied, we found reductions in the concentrations of both the HMWK and the LMWK over time in both the patients who developed restenosis and those who did not. A more detailed analysis found that the patients with restenosis exhibited reductions in HMWK levels 24 hours after the procedure and lower levels of LMWK than patients without restenosis at all time points. The concentrations of plasma and tissue kallikreins also decreased in parallel with the kininogens, but there were no differences in the concentrations of the kallikreins between the patient groups. Kinins are generated by the proteolytic cleavage of kininogens by kallikrein. Therefore, we can infer that the production of kinins in the patients with restenosis was decreased before the procedure.
Studies examining the effect of BK on cell growth have provided contradictory results. For example, BK inhibits the growth of smooth muscle cells (SMCs) and gingival fibroblasts induced by platelet-derived growth factor. 25 These contradictory results again demonstrate the importance of detailed study of the relationship of kinins with the development of restenosis to determine whether targeted therapies for the KKS will be effective. Our study found that the level of kininase II increased significantly in both the patients with and without restenosis over 6 months after their initial procedure; the patients with restenosis have a tendency to have higher plasma levels of kininase II, however, this increase was not statistically significant. Local tissue activity of kininase II has been correlated with the degree of intimal hyperplasia. 33 Systemic inhibition of kininase II has significantly reduced intimal hyperplasia after angioplasty balloon catheter in the carotid of rats in a dose-dependent manner. 34 However, the failure of ACE inhibitor therapy in reducing restenosis rates in humans suggests that BK has a more prominent role in the damaged arteries of human patients than initially predicted from animal models. MMP-2 and -9 are demonstrably involved in the migration of SMCs into the intima, favoring the development of intimal hyperplasia in in vivo models. 35, 36 To elucidate the relationship between MMPs and restenosis further, our study used zymography to analyze the proteolytic activity of MMP-2 and MMP-9 in plasma samples taken from our study patients. In samples taken before the procedure, and 24 hours and 6 months after the procedure, there were no significant differences in the concentrations of these MMPs between the patients who developed restenosis and those who did not. Similar results were found recently by Ribeiro et al 32 who examined the use of nitinol stents and the development of restenosis in patients undergoing peripheral angioplasty. The authors did not find significant relationships between the levels of MMP-2 and -9 and restenosis outcomes. TIMPs have biological effects that extend beyond their role as inhibitors of MMP activity, including regulation of cell proliferation, migration and invasion, anti-angiogenesis, and apoptosis. 16 This study found a lower TIMP-2 level in the patients with restenosis at 6 months after the initial PTA and stent placement than in the patients without restenosis.
The main limitation of this study was the small number of patients, which is reflected by the large standard deviations. There were also no simultaneous comparisons with controls, such as patients with no intervention, angioplasty alone, or angioplasty plus stenting so that we could not compare the inflammatory activities of these procedures. An important consideration to make is that the plasma levels of MMPs, TIMPs, and KKS may not correspond directly to possible levels that would be found directly on the implant sites of stents, which justify any discordant findings between some clinical and experimental studies. It is also appropriate to mention that the timing of samples was limited (after the baseline measurement) to only 24 hours and 6 months.
The precise mechanism underlying in-stent restenosis is not completely understood. Preliminary studies have shown that inflammation may be a contributing factor, but additional investigations must be conducted to understand the association between stent implantation and the inflammatory response in peripheral arteries. This idea is reinforced by the outcomes of different devices, such as covered stents, which have exhibited better primary patency rates than those of conventional nitinol stents.
CONCLUSIONS
This study demonstrates an association between KKS and in in-stent restenosis (lower levels of HMWK and LMWK in patients with restenosis), although we did not observe any association between serum metalloproteinases and the restenosis process. 
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